We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · August 05, 2020

Alternating Cycles of Sunitinib and Everolimus Do Not Prevent Resistance in mRCC

BJU International


Additional Info

BJU International
Randomised Phase II Study Comparing Alternating Cycles of Sunitinib and Everolimus Versus Standard Sequential Administration in First-Line Metastatic Renal Carcinoma (SUNRISES Study)
BJU Int 2020 Jul 12;[EPub Ahead of Print], A Rodriguez-Vida, A Bamias, E Esteban, MI Saez, M Lopez-Brea, D Castellano, C Caballero, J Luis Gonzalez-Larriba, E Calvo, S Macia, A Ravaud, J Bellmunt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading